Introduction: Socioeconomic and demographic conditions in a country can influence tuberculosis incidence and mortality, with nearly 95% of tuberculosis-related deaths occurring in poorer countries. Mozambique is among the 30 countries with the highest TB burden. Objective: The study aimed to estimate the average direct medical cost of treating drug-resistant tuberculosis in 19 health centers in Maputo City, Mozambique. Methods: A retrospective analysis of direct medical costs was conducted on patients aged 18 and older who completed 20-month drug-resistant tuberculosis treatment regimens in Maputo City in 2019. Results: This analysis covered 140 patients who completed a 20-month treatment regimen, with 64.3% (78) being male and 35.7% (62) female. Approximately 50% of the participants were aged between 29 and 47. The average direct medical cost of DRTB treatment was $4789.43, reaching up to $6568.00, with a standard deviation of $753.26, including clinical interventions and treatment. Conclusion: The direct medical costs for a basic treatment package for a patient with drug-resistant TB in Mozambique equal 36 minimum wages. Developing alternative and innovative funding mechanisms and identifying ways to mitigate costs through the use of generic medicines would be beneficial.
References
[1]
WHO (2021) Global Tuberculosis Report 2020. World Health Organization, Geneva. https://www.who.int/publications/i/item/9789240013131
[2]
Bu, Q., Qiang, R., Fang, L., Peng, X., Zhang, H. and Cheng, H. (2023) Global Trends in the Incidence Rates of MDR and XDR Tuberculosis: Findings from the Global Burden of Disease Study 2019. Frontiers in Pharmacology, 14, Article 1156249. https://www.frontiersin.org/articles/10.3389/fphar.2023.1156249 https://doi.org/10.3389/fphar.2023.1156249
[3]
WHO (2023) Global Tuberculosis Report 2022. World Health Organization, Geneva. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022
[4]
Monedero-Recuero, I., Gegia, M., Wares, D.F., Chadha, S.S. and Mirzayev, F. (2021) Situational Analysis of 10 Countries with a High Burden of Drug-Resistant Tuberculosis 2 Years Post-UNHLM Declaration: Progress and Setbacks in a Changing Landscape. International Journal of Infectious Diseases, 108, 557-567. https://doi.org/10.1016/j.ijid.2021.06.022
[5]
Ou, Z.J., Yu, D.F., Liang, Y.H., He, W.Q., Li, Y.Z., Meng, Y.X., et al. (2021) Trends in Burden of Multidrug-Resistant Tuberculosis in Countries, Regions, and Worldwide from 1990 to 2017: Results from the Global Burden of Disease Study. Infectious Diseases of Poverty, 10, Article No. 24. https://doi.org/10.1186/s40249-021-00803-w
[6]
Programa Nacional de Controle da Tuberculose (2021) Relatório de desempenho do PNCT 2017. Misau.
[7]
Programa Nacional de Controle da Tuberculose (2021) Relatório de desempenho do PNCT 2021. Misau.
[8]
Mutemba, C.M., Schindele, A., Munyangaju, I., Ramanlal, N., Manhiça, I., José, B., et al. (2023) Contribution of Xpert® MTB/RIF to Pediatric TB Diagnosis in Mozambique. International Journal of Tuberculosis and Lung Disease, 27, 419-421. https://doi.org/10.5588/ijtld.22.0479
[9]
Programa Nacional de Controle da Tuberculose (2021) Relatório Anual do Programa 2019. Misau.
[10]
Programa Nacional de Controle da Tuberculose (2023) Manual de Manejo Clínico e Programático da Tuberculose Multirresistente. Misau.
[11]
Fitzpatrick, C. and Floyd, K. (2012) A Systematic Review of the Cost and Cost Effectiveness of Treatment for Multidrug-Resistant Tuberculosis. PharmacoEconomics, 30, 63-80. https://doi.org/10.2165/11595340-000000000-00000
[12]
Madan, J.J., Rosu, L., Tefera, M.G., Van Rensburg, C., Evans, D., Langley, I., et al. (2020) Economic Evaluation of Short Treatment for Multidrug-Resistant Tuberculosis, Ethiopia and South Africa: The STREAM Trial. Bull World Health Organ, 98, 306-314. https://doi.org/10.2471/BLT.19.243584
[13]
Hwang, T.J. and Keshavjee, S. (2014) Global Financing and Long-Term Technical Assistance for Multidrug-Resistant Tuberculosis: Scaling up Access to Treatment. PLOS MEDICINE, 11, e1001738. https://doi.org/10.1371/journal.pmed.1001738
[14]
Alemayehu, S., Yigezu, A., Hailemariam, D. and Hailu, A. (2020) Cost-Effectiveness of Treating Multidrug-Resistant Tuberculosis in Treatment Initiative Centers and Treatment Follow-Up Centers in Ethiopia. PLOS ONE, 15, e0235820. https://doi.org/10.1371/journal.pone.0235820
[15]
Fautrel, B., Boonen, A., Wit, M, De Grimm, S., Joore, M. and Guillemin, F. (2020) Cost Assessment of Health Interventions and Diseases. RMD Open, 6, e001287. https://doi.org/10.1136/rmdopen-2020-001287
[16]
Meltzer, M.I. (2001) Introduction to Health Economics for Physicians. The Lancet, 358, 993-998. https://doi.org/10.1016/S0140-6736(01)06107-4
[17]
INE (2023) Estatisticas dos Distritos da Cidade de Maputo—2017-2021. Instituto Nacional de Estatistica, Maputo. https://www.ine.gov.mz/web/guest/d/estatisticas-dos-distritos-da-cidade-de-maputo-2017-2021
[18]
Lisboa, O. (2023) Civil Service Minimum Wage Doubles in Mozambique. Radio France Internationale (RFI), Mozambique.
[19]
The Global Fund (2023) The Global Fund | Data Explorer—Datasets: Mozambique. https://data.theglobalfund.org/location/moz/disbursements/time-cycle
[20]
Lange, C., Abubakar, I., Alffenaar, J.W.C., Bothamley, G., Caminero, J.A., Carvalho, A.C.C., et al. (2014) Management of Patients with Multidrug-Resistant/Extensively Drug-Resistant Tuberculosis in Europe: A TBNET Consensus Statement. European Respiratory Journal, 44, 23-63. https://doi.org/10.1183/09031936.00188313
[21]
Oga-Omenka, C., Tseja-Akinrin, A., Sen, P., Mac-Seing, M., Agbaje, A., Menzies, D. and Zarowsky, C. (2020) Factors Influencing Diagnosis and Treatment Initiation for Multidrug-Resistant/Rifampicin-Resistant Tuberculosis in Six Sub-Saharan African Countries: A Mixed-Methods Systematic Review. BMJ Glob Health, 5, e002280. https://doi.org/10.1136/bmjgh-2019-002280
[22]
Endo, Y., Jaramillo, J. and Yadav, R.P.H. (2022) Patient-and Health-System-Related Barriers to Treatment Adherence for Patients with Drug-Resistant Tuberculosis in the Philippines: A Mixed-Methods Study. Tuberculosis Research and Treatment, 2022, Article ID: 6466960. https://doi.org/10.1155/2022/6466960
